Study Protocol for the TIGHTEN Study Comparing the Effects of Tofogliflozin and Glimepiride on Skeletal Muscle Mass in Patients with Type 2 Diabetes without Obesity: A Prospective, Multicenter, Open-Label, Randomized, Parallel Group Trial in Japan
- 1Department of Diabetology and Endocrinology, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Kahoku, Ishikawa 920-0293 Japan
- 2Department of Internal Medicine, Kanazawa Nakade Clinic, 294-7 Chikaoka-machi, Kanazawa, Ishikawa 920-8217 Japan
- 3Department of Internal Medicine, Asanogawa General Hospital, 83 Kosaka-machi, Kanazawa, Ishikawa 920-8621 Japan
Abstract
Introduction: Although sodium-glucose cotransporter 2 (SGLT2) inhibitors are associated with a lower risk of hypoglycemia, they may result in weight reduction, and provide additional benefits for cardiovascular disease, chronic kidney disease, and heart failure. However, their use in Japanese individuals with type 2 diabetes (T2D)—many of whom are older and without obesity—raises concerns regarding sarcopenia. This study aims to investigate the impact of the SGLT2 inhibitor tofogliflozin, compared with sulfonylurea glimepiride, on skeletal muscle mass in patients with T2D without obesity.
Methods: This study is a prospective, multicenter, open-label, randomized, parallel group, comparative trial. Adult Japanese patients with T2D with a body mass index of < 25 kg/m2 and a glycated hemoglobin (HbA1c) level of 7.0 to < 10.0% will be randomly assigned in a 1:1 ratio to receive tofogliflozin (20 mg orally/day) or glimepiride (0.5–4 mg orally/day) for 24 weeks. The primary endpoint is the change in total skeletal muscle mass to total body weight ratio from baseline to 24 weeks. The key secondary endpoints include the percentage change in total skeletal muscle mass to total body weight ratio and the change or percentage change in skeletal muscle mass index from baseline to 24 weeks. In total, 56 participants were calculated to be required, considering a dropout rate 15%, a two-sided alpha of 0.05, and a power of 0.9.
Planned Outcomes: Participant recruitment commenced in April 2024 and concluded in June 2025. The complete findings of this study are anticipated to be published in 2027. We expect that the results will elucidate the impact of SGLT2 inhibitors on skeletal muscle mass in individuals with T2D without obesity, thereby addressing concerns related to sarcopenia.
Trial Registration: Japan Registry of Clinical Trials (jRCT) (No. jRCTs041240011); registered 10 April 2024, https://jrct.mhlw.go.jp/en-latest-detail/jRCTs041240011.
Related
- Prophylactic antibiotics for pancreaticoduodenectomy: study protocol for a multicenter randomized controlled trial comparing tazobactam/piperacillin versus ampicillin/sulbactam.
- NMA plus antitumor therapy versus antitumor therapy alone in patients with BCLC stage B or C hepatocellular carcinoma and pre-cachexia or cachexia: protocol for a prospective, multicenter, randomized, open-label phase II trial
- A Prospective, Randomized, Non-inferiority Clinical Protocol Comparing the Efficacy and Safety of Single-port versus Multiport Extraperitoneal Robotic Radical Prostatectomy Using the KangDuo Robotic System
- Comparing the Recurrence Patterns of Reduced-Margins vs. RTOG-Protocol in Adjuvant Chemoradiation of High-Grade Gliomas: A Multicenter, Open-Label, Randomized Controlled Trial
- Long‐term effects of tofogliflozin on renal function in patients with type 2 diabetes: A retrospective multicenter study
BibTeX
@article{takeda2026study,
title = {{Study Protocol for the TIGHTEN Study Comparing the Effects of Tofogliflozin and Glimepiride on Skeletal Muscle Mass in Patients with Type 2 Diabetes without Obesity: A Prospective, Multicenter, Open-Label, Randomized, Parallel Group Trial in Japan}},
author = {Yasutaka Takeda and Tsubasa Ozawa and Maki Ikoma and Keiji Shimada and Reina Saito and Atsushi Nakagawa and Toshitaka Sawamura and Naoki Kumashiro},
journal = {Diabetes Therapy},
year = {2026},
month = sep,
doi = {10.1007/s13300-026-01920-1},
url = {https://doi.org/10.1007/s13300-026-01920-1},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Study Protocol for the TIGHTEN Study Comparing the Effects of Tofogliflozin and Glimepiride on Skeletal Muscle Mass in Patients with Type 2 Diabetes without Obesity: A Prospective, Multicenter, Open-Label, Randomized, Parallel Group Trial in Japan
AU - Yasutaka Takeda
AU - Tsubasa Ozawa
AU - Maki Ikoma
AU - Keiji Shimada
AU - Reina Saito
AU - Atsushi Nakagawa
AU - Toshitaka Sawamura
AU - Naoki Kumashiro
PY - 2026
DA - 2026/09/15
JO - Diabetes Therapy
DO - 10.1007/s13300-026-01920-1
UR - https://doi.org/10.1007/s13300-026-01920-1
AB - Introduction: Although sodium-glucose cotransporter 2 (SGLT2) inhibitors are associated with a lower risk of hypoglycemia, they may result in weight reduction, and provide additional benefits for cardiovascular disease, chronic kidney disease, and heart failure. However, their use in Japanese individuals with type 2 diabetes (T2D)—many of whom are older and without obesity—raises concerns regarding sarcopenia. This study aims to investigate the impact of the SGLT2 inhibitor tofogliflozin, compared with sulfonylurea glimepiride, on skeletal muscle mass in patients with T2D without obesity. Methods: This study is a prospective, multicenter, open-label, randomized, parallel group, comparative trial. Adult Japanese patients with T2D with a body mass index of < 25 kg/m2 and a glycated hemoglobin (HbA1c) level of 7.0 to < 10.0% will be randomly assigned in a 1:1 ratio to receive tofogliflozin (20 mg orally/day) or glimepiride (0.5–4 mg orally/day) for 24 weeks. The primary endpoint is the change in total skeletal muscle mass to total body weight ratio from baseline to 24 weeks. The key secondary endpoints include the percentage change in total skeletal muscle mass to total body weight ratio and the change or percentage change in skeletal muscle mass index from baseline to 24 weeks. In total, 56 participants were calculated to be required, considering a dropout rate 15%, a two-sided alpha of 0.05, and a power of 0.9. Planned Outcomes: Participant recruitment commenced in April 2024 and concluded in June 2025. The complete findings of this study are anticipated to be published in 2027. We expect that the results will elucidate the impact of SGLT2 inhibitors on skeletal muscle mass in individuals with T2D without obesity, thereby addressing concerns related to sarcopenia. Trial Registration: Japan Registry of Clinical Trials (jRCT) (No. jRCTs041240011); registered 10 April 2024, https://jrct.mhlw.go.jp/en-latest-detail/jRCTs041240011.
SN - 1869-6953
SN - 1869-6961
ER -